Towards broad protection against Ebolaviruses
Related Experiment Video
Updated: Jun 6, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
1Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, IFR128 Biosciences Gerland, Lyon Sud, 21 av. Tony Garnier, 69365 Lyon cedex 7, France. sylvain.baize@inserm.fr
Abstract:
The Ebola and Marburg viruses (from the filovirus family) induce deadly hemorrhagic fevers for which there is currently no licensed vaccine or treatment. Frequent outbreaks have occurred in sub-Saharan Africa, in humans and nonhuman primates over the last 15 years or so and constitute a major public health problem. Of particular concern, a new species of Ebolavirus recently emerged in Uganda, highlighting the high potential of these viruses to evolve and the need to develop 'broad-spectrum' vaccines against filoviruses. Hensley et al. used their well studied vaccine platform based on DNA vectors and recombinant, replication-defective, adenoviruses producing Ebolavirus glycoproteins to protect cynomolgus monkeys against a heterologous challenge with the new species. Further developments are required before this experimental approach could be adapted for field use in humans, but this study nevertheless constitutes a proof-of-concept for broad protection against Ebolaviruses.
More Related Videos
10:11Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
12:20Bacterial Artificial Chromosomes: A Functional Genomics Tool for the Study of Positive-strand RNA Viruses
Published on: December 29, 2015
Related Concept Videos
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Cross-reactivity
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes